Postherpetic neuralgia in the elderly

R. W. Johnson,1 J. McElhaney2

SUMMARY
Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) or ‘shingles’ and affects a significant proportion of HZ patients with the disease, with the elderly being most frequently and seriously affected. Characterised by various types of pain (constant, intermittent and stimulus evoked) that persist between 3 months and many years after the resolution of the HZ rash, PHN can have a severe impact on the patient’s quality of life and functional ability. PHN remains highly resistant to current treatments. In this review, we discuss the epidemiology, clinical features and management of PHN in the elderly and the potential of vaccination against varicella zoster virus as a means to prevent HZ, and thus decrease the incidence and severity of PHN.

Introduction
After a primary varicella infection (chickenpox), the varicella zoster virus (VZV) can remain persistent but clinically latent in the sensory nerve ganglia for many years before being reactivated and becoming manifest clinically as herpes zoster (HZ) or ‘shingles’ (1–4). HZ is characterised by a skin rash that is localised to the sensory region of the affected ganglia and is often preceded or accompanied by acute pain or itching. Pain may persist for months or even years, and this postherpetic neuralgia (PHN) is the most common and debilitating complication of HZ. There is currently no consensus definition for PHN. However, data that identify three distinct phases of pain (acute herpetic neuralgia, subacute herpetic neuralgia and chronic pain or PHN) in HZ suggest that PHN might be best defined as pain lasting at least 3 months after resolution of the rash (5–7). PHN is associated with significant loss of function and reduced quality of life, particularly in the elderly (8), and is highly resistant to treatment. Management of PHN is currently limited to antiviral therapy addressing the underlying cause (VZV infection) and analgesics for the symptomatic treatment of acute pain. This review focuses on the epidemiology, clinical features, management and prevention of PHN in the elderly.

Epidemiology of HZ and PHN
Herpes zoster is a relatively common condition; the incidence of acute HZ in the general population in Europe ranges from about 1.2 to 5.2 per 1000 person-years (annual events per 1000 population) (9–15). There is a strong correlation between the incidence of HZ and increasing age, with a marked rise in incidence at the age of 50–60 years and older (9,10,14). The lifetime risk of HZ is estimated to be up to 25% in the general population, thus one in four people may experience HZ in their lifetime. This risk rises to 50% in those aged > 85 years (16,17).

Herpes zoster is more common in individuals with immunosuppression subsequent to HIV infection or prophylaxis to avoid rejection of organ transplants,
certain malignancies or treatment thereof, or treat-
ment for inflammatory or autoimmune disease (18).

Of patients with HZ, approximately 14% will
develop complications, the most common of which
is PHN. Estimates of the prevalence of PHN vary
widely depending upon the definition of PHN used,
the study methodology and the study population.
PHN persisting at 3 months may occur in 10–20% of
HZ patients aged > 50 years (15,19–21). Other
less frequently occurring complications may be neu-
rological (e.g. anaesthesia in the affected dermatome,
motor paresis), ophthalmic (e.g. pan ophthalmitis,
keratitis, scleritis, uveitis and loss of corneal sensa-
tion), cutaneous (e.g. scarring, bacterial superinfections
of HZ lesions), visceral, or may involve
systemic dissemination of the virus (e.g. cerebral vas-
culitis, pneumonia) (22,23).

Age is the predominant predictor of PHN (24,25).
In a UK primary-care study, the prevalence of PHN
(3-month definition) increased markedly with age:
from 8% at age 50–54 years to 21% at age 80–
84 years (15). Other risk factors for PHN include
prodromal pain, severe acute pain, rash severity and,
in some cases, concomitant disease (26,27). There is
also evidence that PHN is more common in women
than in men (15,28).

Throughout Europe, the elderly population is
expanding rapidly: it is estimated that by 2040 the
population aged > 80 years will have doubled to
almost 10% of the total population (29). An upward
trend in the incidence of HZ and particularly in
PHN that has already been observed is thus expected
to continue (30). As it is the elderly who sustain the
greatest burden caused by PHN, in terms of pain
and suffering as well as medical costs (31), this
demographical shift will represent a considerable
burden on the healthcare and social system.

Clinical features of PHN

Postherpetic neuralgia can manifest as different kinds
of pain. It may present as constant pain, character-
ised by burning, aching or throbbing; as intermittent
pain, including stabbing and shooting pain; or as
stimulus-evoked pain, such as allodynia (the experi-
encing of pain after a normally non-painful stimulus,
such as a cold breeze or a light touch from clothing)
(16).

While PHN will resolve in most cases, it may per-
sist in some patients for an extended period. A long-
term study demonstrated that 9% (11 out of 12 of
whom were aged > 51 years) still had pain at 1 year
after resolution of the rash (32). In a recent rando-
mised, double-blind, placebo-controlled, multi-centre
study in the USA, the Shingles Prevention Study, in
the placebo group, in people aged ≥ 60 years, 80 out
of 642 (12.4%) had PHN at 3 months and in 41% of
these cases PHN persisted for at least 182 days (19).
Other studies have reported that PHN can last for
years (21).

The negative impact of PHN on the quality of life
can be similar to that caused by life-threatening dis-
eeses or serious psychological conditions. PHN can
have a significant effect on many aspects of a
patient’s life, causing chronic fatigue, sleep disorders,
difficulty in concentrating, depression and anxiety,
anorexia, loss of bodyweight and social isolation
(33,34). PHN can interfere with basic and essential
activities of daily living, such as dressing, bathing,
mobility, travelling, shopping, cooking and house-
work, thus considerably impairing an individual’s
functional ability and, in some cases, causing an
active member of the community to become rela-
atively inactive and housebound (16,34). The more
severe the pain experienced, the more significant the
impact on quality of life; in a study of 50 patients
with HZ, those with pain scores ≥ 4 out of 10 expe-
rienced the greatest interference with daily living,
including general activity, work, sleep and enjoyment
of life (35).

With more than 20% of the population of the
European Union already aged > 60 years (36) and
continuing increases in life expectancy predicted,
attention is being focused on the concept of ‘healthy
aging’. Prevention of HZ and the disability associated
with PHN would help people to remain active in old
age, compressing the period of senescence to nearer
the end of life (37,38).

Management of HZ and PHN

The delayed or atypical presentation of HZ often
prevents timely treatment; studies suggest that only
25–50% of patients may receive antivirals at an early
stage (32,39). Antiviral agents (acyclovir, valaciclovir,
famciclovir and brivudin) can alleviate acute pain
and reduce the risk of long-term pain in patients
with HZ (40); however, it is unclear to what extent
they reduce the incidence of prolonged PHN. Corti-
scosteroids, given either orally (41,42) or as a single
epidural injection (43), have also shown beneficial
effects on acute pain, but they do not prevent PHN
(44).

Optimal pain control is difficult to achieve with
currently available medications, and no single treat-
ment is completely effective for all patients; in clini-
cal practice, the combinations of analgesic drugs
used usually only achieve partial pain relief (45).
Moreover, the complex and heterogeneous nature of
the mechanisms that contribute to PHN suggest that
adequate symptom relief by a single agent is unlikely (46). The benefits and disadvantages of the main PHN therapies are summarised in Table 1.

A recent meta-analysis has demonstrated evidence of analgesic efficacy in established PHN for several orally administered therapies: tricyclic antidepressants (TCAs), opioids (including tramadol) and anticonvulsants (gabapentin and pregabalin) (45). TCAs and gabapentin are recommended as first-line therapy for this condition, being almost equally efficacious in the

Table 1 The beneficial effects and potential limitations of common treatments for postherpetic neuralgia

| Class                     | References | Treatment | Benefits | Limitations                                                                 |
|---------------------------|------------|-----------|----------|-----------------------------------------------------------------------------|
| **Systemic**              |            |           |          |                                                                             |
| Tricyclic antidepressants | 45–48      | In general| Effect on pain | Poor AE profile: anticholinergic AEs (drowsiness, dry mouth, constipation, increased appetite) Rare: blurred vision, urinary retention, glaucoma exacerbation, mood change |
| Amitriptyline             |            | Effect on pain in some patients |                                                                             |
| Nortriptyline             |            | Effect on pain in some patients |                                                                             |
| Desipramine               |            | Less sedating than other TCAs. Less toxic side effect profile than amitriptyline |                                                                             |
| Maprotiline               |            | Effect on pain in some patients |                                                                             |
| Anticonvulsants           | 40,45,47,48| Gabapentin | Higher benefit-to-AE ratio than TCAs. Effect on pain, sleep interference, positive effect on mood, QoL | Lower efficacy than amitriptyline, poor side effect profile AEs: somnolence, dizziness, ataxia, peripheral oedema, infection (all usually minor) Caution required in patients with myasthenia gravis or impaired renal function |
| Pregabalin                |            | Effect on pain, sleep | Mild-to-moderate dizziness, somnolence, headache, dry mouth | Little/no pain benefit Confusion and sedation in elderly patients Dermatological complications more severe than other drugs in this class |
| Carbamazepine             |            |           |          |                                                                             |
| Lamotrigine               |            | Some evidence of neuropathic pain benefit | Stronger opioids are recommended to be administered in a specialist clinic only and are therefore not first-line therapy AEs: respiratory depression, constipation, sedation, nausea, vomiting, delirium, dependence |
| **Opioids**               | 40,45,47,48| In general| Effect on pain. May be preferable to TCAs |                                                                             |
| Morphin                  |            | Effect on pain |                                                                             |
| Oxycodone                |            | Effect on pain | May provide significant pain relief |                                                                             |
| Levoorphanol             |            | Effect on pain |                                                                             |
| tramadol                 |            | May provide satisfactory pain relief |                                                                             |
| Ketamine                 | 45,47,48   | Ketamine  | May be effective in some patients (poor evidence available) | AEs: itching, painful induration at injection site, nausea, fatigue, dizziness, psychodosleptic/cognitive effects Not effective in PHN |
| Dextromethorphan          |            |           |          |                                                                             |
| **NMDA antagonists**     | 45,47,48   | Ketamine  | May be effective in some patients (poor evidence available) | AEs: itching, painful induration at injection site, nausea, fatigue, dizziness, psychodosleptic/cognitive effects Not effective in PHN |
| Antagonists of the N-methyl D-aspartate receptor | Dextromethorphan | Ketamine | May be effective in some patients (poor evidence available) | AEs: itching, painful induration at injection site, nausea, fatigue, dizziness, psychodosleptic/cognitive effects Not effective in PHN |
| **Topical**              |            |           |          |                                                                             |
| Amino-amide              | 45,48      | i.v. Lidocaine | No significant effect on pain | AEs: mild nausea, light-headedness |
| **Capsaicinoid**         | 45,48      | Capsaicin  | Effect on pain | Pungent Burning sensation |

AE, adverse event; QoL, quality of life; TCA, tricyclic antidepressant; NMDA, N-methyl-D-aspartate; PHN, postherpetic neuralgia.
treatment of PHN (40,45,47), although TCAs are associated with more minor adverse events than gabapentin and are more likely to interact with other drugs (48), a particular concern in elderly patients who are likely to be using concomitant medications for chronic diseases. Pregabalin, an analogue of gabapentin, has shown to significantly decrease pain and improve sleep in randomised, placebo-controlled trials (49,50). Although opioids also appear to be effective in controlling neuropathic pain, the age and frailty of the patient limit the prescription of such drugs known to produce moderate-to-severe side effects such as nausea and constipation (40).

Topical application of lidocaine is a well-tolerated supplementary treatment for PHN, and patches containing lidocaine are an approved treatment in the United States and Europe (51,52). There is conflicting evidence for the use of topical lidocaine (patches or gel) or a eutectic mixture of local anaesthetics (EMLA®, AstraZeneca, Miami, FL, USA) in the treatment of PHN with allodynia; while a recent systematic review found insufficient evidence to support its use (53). Previous reviews have concluded that lidocaine should be a first-line adjunctive treatment in this context (45,52,53). The topical use of capsaicin has been shown to provide significant pain relief in two randomised trials, although patient response can be delayed and discomfort and burning sensations can limit compliance (45,53).

While not supported by evidence from randomised clinical trials, some clinicians treat PHN with peripheral, epidural, intrathecal or sympathetic nerve blockade with local anaesthetics and/or steroids. Such interventions have also been used in the treatment of HZ, but results for the prevention and treatment of PHN have been disappointing as only short-term analgesic effects have been demonstrated (43,54,55). Two studies on intrathecal or epidural administration of methylprednisolone with or without lidocaine (56,57) appear to show considerable efficacy in the intrathecal groups, although the safety of this technique remains uncertain (58). Until these studies have been replicated, such treatment cannot be recommended.

Non-pharmacological treatments for PHN include transcutaneous electrical nerve stimulation, acupuncture and other alternative therapies. While the effectiveness of such interventions has not been adequately investigated, the low risks associated with their use suggest that they may be considered in combination with conventional treatment or in older patients who fail to respond to first-line treatments (52). Behavioural therapies such as relaxation techniques have been used with positive effects (52), and the potential benefits of psychological support for treatment of depression and pain-management strategies should not be ignored (54).

Currently available treatments are thus of limited efficacy and are associated with adverse events that are poorly tolerated, especially by elderly patients. There is a need for long-term randomised-controlled clinical trials to assess the efficacy of combinations of medications and new therapies (59).

**Prevention of PHN**

The increased risk and severity of HZ and PHN with advancing age are associated with an age-related decline in VZV-specific T-cells (16). VZV-specific T-cell immunity could eventually fall to below a threshold at which symptomatic VZV reactivation is likely to occur, thereby increasing the risk of HZ (60). A prophylactic vaccine that can increase VZV-specific T-cell immunity represents a promising clinical approach to limit the debilitating complications of HZ, including PHN (16,60,61). Indeed, HZ itself is associated with an increase in VZV-specific T-cells, and recurrences of HZ in immunocompetent individuals are rare (22,60). In the Shingles Prevention Study, the efficacy of a live attenuated Oka/Merck VZV vaccine in decreasing the incidence and/or severity of HZ and PHN was evaluated in a trial involving 38,546 individuals aged ≥60 years (19). End-points included burden of illness (BOI) due to HZ, a measure reflecting the incidence, severity and duration of HZ-associated pain and discomfort (primary end-point) (19) and the incidence of HZ and PHN.

Vaccination markedly decreased both the morbidity associated with HZ and the incidence of PHN for a mean duration of at least 3 years (19,62). The BOI of HZ was significantly reduced in vaccine-recipients (61% reduction; p < 0.001 vs. placebo), and a significant reduction in the incidence of PHN at 3 months (67% reduction; p < 0.001 vs. placebo) was observed (19). Efficacy against HZ, a secondary end-point, was 51% (p < 0.001 vs. placebo). Although HZ vaccine efficacy was greater at age 60–70 years (64%) than at age >70 years (38%), efficacy for reducing HZ BOI and PHN was similar in both age groups (19).

The vaccine was safe and well tolerated. There was no difference in overall mortality between the vaccine and placebo groups. The most commonly observed adverse events observed in the Shingles Prevention Study occurred at the local injection site (48% in vaccine-recipients vs. 16% in placebo-recipients; p < 0.05), while systemic adverse events occurred in 6.3% of vaccine-recipients and 4.9% of placebo-recipients (p < 0.05); headache being the most frequent reported (19).
This vaccine (Zostavax; Oka/Merck, Whitehouse Station, NJ) has been approved by the US Food and Drug Administration and by the European Medicines Agency. It is indicated for the prevention of HZ in individuals aged 60 years (US) or 50 years (EU) and older and is contraindicated in immunocompromised patients, children and pregnant women. Recent studies indicate that vaccination of an aged population is likely to be cost-effective from the healthcare-payer perspective (63).

Conclusion

HZ and associated PHN can have a considerable impact on quality of life. PHN can be debilitating for some patients and may be a significant contributing factor to the progression of disability in older people. PHN is difficult to treat and is often refractory to traditional therapeutic approaches and standard analgesic regimens. More effective strategies for the management of HZ and related pain are essential. The prevention of HZ by vaccination has the potential to reduce the incidence and severity of PHN.

Acknowledgement

We thank Angus Thomson and Heidi Mattock for editorial assistance.

Authors' contribution

RW Johnson: drafting/critical revision/approval of article. J McElhaney: critical review/approval of article.

References

1 Hope-Simpson R. Studies on shingles: is the virus ordinary chicken pox virus? Lancet 1954; 2: 1299–302.
2 Weller T, Witton H, Bell E. The etiologic agents of varicella and herpes zoster: isolation, propagation, and cultural characteristics in vitro. J Exp Med 1958; 108: 843–68.
3 Strauss SE, Reinhold W, Smith HA et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med 1984; 311: 1362–4.
4 Lungo O, Armuzziato PW, Gershon A et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA 1995; 92: 10980–4.
5 Arani RB, Soong SJ, Weiss HL et al. Phase specific analysis of zoster associated pain data: a new statistical approach. Stat Med 2001; 20: 2429–39.
6 Desmond RA, Weiss HL, Arani RB et al. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manage 2002; 23: 510–6.
7 Dworkin RH. Post-herpetic neuralgia. Herpes 2006; 13 (Suppl. 1): 21A–7A.
8 Oster G, Harding G, Dukes E, Edelberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6: 356–63.
9 Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9–20.
10 Paul E, Thiel T. Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area. Hautarzt 1996; 47: 604–9.
11 di Luzio Paparatti U, Arpinelli F, Visona G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999; 38: 116–20.
12 Chidiac C, Bruxelle J, Daures JP et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33: 62–9.
13 Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003; 70 (Suppl. 1): 59–14.
14 de Melker H, Berbers G, Hahne S et al. The epidemiology of varicella and herpes zoster in the Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24: 3946–52.
15 Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2008; 9: 1–10.
16 Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32: 1481–6.
17 Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol 1993; 4: 222–30.
18 Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002; 347: 340–6.
19 Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271–84.
20 Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24: 1308–14.
21 Johnson RW, Rice AS. Pain following herpes zoster: the influence of changing population characteristics and medical developments. Pain 2007; 128: 3–5.
22 Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella Zoster Virus: Virology and Clinical Management. Cambridge, England: Cambridge University Press, 2000: 246–75.
23 Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain 2008; 9 (Suppl. 1): S3–9.
24 Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157: 1217–24.
25 Coen PG, Scott F, Leedham-Green M et al. Predicting and preventing post-herpetic neuralgia: are current risk factors useful in clinical practice? Eur J Pain 2006; 10: 695–700.
26 Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545–51.
27 Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008; 80: 1646–52.
28 Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3: 335–42.
29 Giannakouris K. Ageing characterises the demographic perspectives of the European societies. Eurostat Stat Focus 2008; 72. http://epp.eurostat.ec.europa.eu (accessed September 2008).
30 Brisson M, Edmunds WJ, Law B et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 303–14.
31 Brisson M, Pellisier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Humana Vaccines 2008; 4: 238–43.
32 Scott FT, Leedham-Green ME, Barrett-Muir WY et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70 (Suppl. 1): S24–30.
33 Coplan PM, Schmader K, Nikas A et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory. *J Pain* 2004; 5: 344–56.
34 Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. *Clin J Pain* 2002; 18: 350–4.
35 Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. *Neurology* 1995; 45: S52–3.
36 Pearce D, Bovagnet FC. The demographic situation in the European Union. *Popul Trends* 2005; 119: 7–15.
37 Fries JF. Aging, natural death, and the compression of morbidity. *N Engl J Med* 1980; 303: 130–5.
38 Kalache A, Aboderin I, Hoskins I. Compression of morbidity and active ageing: key priorities for public health policy in the 21st century. *Bull World Health Organ* 2002; 80: 243–4.
39 Opstelten W, van Essen GA, Moons KGM et al. Do herpes zoster patients receive antivirals? A Dutch national survey in general practice *Fam Pract* 2005; 22: 523–8.
40 Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. *Expert Opin Pharmacother* 2004; 5: 551–9.
41 Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. *Clin Infect Dis* 1996; 22: 341–7.
42 Whaley RJ, Weiss H, Gnann JW Jr et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. *Ann Intern Med* 1986; 125: 376–83.
43 van Wijck AJ, Opstelten W, Moons KGM et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. *Lancet* 2006; 367: 219–24.
44 He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. *Cochrane Database Syst Rev* 2008; 1: CD003582.
45 Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. *PLoS Med* 2005; 2: e164.
46 Argoft CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. *J Pain Symptom Manage* 2004; 28: 396–411.
47 Johnson R, Patrick D (eds). *Improving the Management of Varicella Herpes Zoster and Zoster-Associated Pain. Recommendations from the IHMF Management Strategies Workshop*. Management Strategies in Herpes Series. Worthing: PAREXEL MMS, 2001.